Back to Breast Cancer
NCT03701334
NCT03701334
Who may be able to join
Who might be able to join this trial:
- You have signed and dated a consent form before any trial-related tests begin.
- You are 18 years old or older when you sign the consent form.
- You are either male, or a female with a known menopausal status (either confirmed postmenopausal through surgery, age, hormone tests, or periods stopping for 12+ months, or confirmed premenopausal — all women who don't meet the postmenopausal criteria are considered premenopausal for this trial).
- You have been confirmed by biopsy or tissue sample to have a specific type of breast cancer (invasive adenocarcinoma) in one breast, and your diagnosis was made within the past 18 months.
- Your breast cancer tests positive for hormone receptors (estrogen receptor and/or progesterone receptor).
- Your breast cancer tests negative for the HER2 protein (confirmed by standard laboratory testing).
- You have stored tumour tissue available from your surgery that can be sent to a central lab (except for patients enrolling in China; and if you had treatment before surgery and the tumour disappeared completely, tissue from before that treatment is required).
- Your surgeon removed the tumour completely, with no cancer cells found at the edges of the removed tissue, and your cancer falls into a specific stage category (Stage III, Stage IIB, or certain Stage IIA cases — confirm exact stage eligibility with the trial site).
- If chemotherapy was recommended for you, you have already finished it before screening for this trial.
- If radiation therapy was recommended for you, you have already finished it before screening for this trial.
- There is no medical reason you cannot take the hormone therapy used in this trial, and you are planned to take it for at least 5 years.
- You may have already started standard hormone therapy, but you must join the trial (be randomised) within 12 months of first starting that therapy.
- You are generally well enough to carry out everyday activities with little or no limitation (as measured by a standard doctor's scale called ECOG Performance Status 0 or 1).
- Your blood counts, kidney function, liver function, and certain blood mineral levels (potassium, magnesium, calcium) are within acceptable ranges based on recent lab tests.
- Your heart's electrical activity, measured by a standard heart tracing (ECG), shows a normal heart rhythm (specific electrical interval below 450 milliseconds and resting heart rate between 50 and 90 beats per minute).
- You are willing and able to attend scheduled visits, follow the treatment plan, and complete all required tests and procedures.
- If you are a woman who could become pregnant, you have a confirmed negative pregnancy blood test within 14 days before joining the trial.
- If you are a woman who could become pregnant, you are willing to use a highly effective non-hormonal method of contraception during treatment and for 21 days after stopping treatment (acceptable methods include complete abstinence consistent with your usual lifestyle, surgical sterilisation, a vasectomised partner, or a copper intrauterine device — hormonal contraception is not allowed in this trial).
Who may not be able to join:
- You have previously received a type of cancer drug called a CDK4/6 inhibitor.
- You have used tamoxifen, raloxifene, or aromatase inhibitors (AIs) to reduce breast cancer risk or to treat osteoporosis within the past 2 years, or you are currently using hormone replacement therapy (HRT).
- You have previously received high cumulative doses of certain chemotherapy drugs called anthracyclines (above specific dose thresholds — confirm with trial site).
- You have a known allergy or sensitivity to the ingredients in the trial drugs, including certain rare sugar metabolism conditions or soy allergy (confirm with trial site).
- Your breast cancer has spread to distant parts of the body (stage IV), or there is evidence the cancer has come back after surgery.
- You are currently receiving any other cancer treatment, apart from the hormone therapy allowed in this trial.
- You have had major surgery, chemotherapy, or radiotherapy within the 14 days before joining the trial.
- You are still experiencing significant side effects from previous cancer treatments that have not sufficiently recovered (hair loss, certain nerve-related side effects, and some others may be exceptions — confirm with trial site).
- You currently have or recently had another invasive cancer, and its treatment finished within the past 2 years (certain treated
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Trial details
Status
Active, Not Recruiting
Phase
Phase 3
Sponsor
Novartis Pharmaceuticals
Registry
clinicaltrials_gov
Start date
7 December 2018
Est. completion
29 May 2030
Where this trial is recruiting
🇦🇷 Argentina
🇦🇺 Australia
🇦🇹 Austria
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇦 Canada
🇨🇳 China
🇫🇷 France
🇩🇪 Germany
🇭🇺 Hungary
🇮🇪 Ireland
🇮🇹 Italy
🇵🇱 Poland
🇷🇴 Romania
🇷🇺 Russia
🇰🇷 South Korea
🇪🇸 Spain
🇹🇼 Taiwan
🇬🇧 United Kingdom
🇺🇸 United States
24 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Invasive Disease-Free Survival (iDFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.